iCAD, Inc., a New Hampshire based provider of advanced image analysis, workflow solutions, and radiation therapies for the early identification and treatment of cancer, announced today that its Xoft electronic brachytherapy system has been recently adopted at a number of leading hospitals across the country, including Diablo Valley Oncology/Hematology (Pleasant Hill, CA), Exeter Hospital (Exeter, NH), Memorial Hospital Chattanooga (Chattanooga, TN), Florida Hospital Tampa (Tampa, FL), Rockford Memorial Hospital (Rockford, IL), Rose Medical Center (Denver, CO), and Vanderbilt Medical Center (Nashville, TN).
The Xoft® Axxent eBxTM system for intraoperative radiation therapy (IORT) is designed to reduce the normally required radiation treatment regimen for breast cancer patients. The current standard for treating early stage breast cancer calls for a lumpectomy, medical therapy, and a 5-7 week course of daily Whole Breast External Beam Radiation Therapy (WBEBRT). IORT allows doctors to give a high dose of radiation to the tumor bed during a lumpectomy, reducing or eliminating the need for follow-up radiation treatments. A single IORT dose may be as effective in treating such tumors as 10-20 daily radiation doses.
iCAD CEO Ken Ferry spoke of the increased acceptance of the Axxent eBx system and IORT: “The recent adoption of the Axxent eBx System is an increasing endorsement of electronic brachytherapy and IORT as a safe and effective method of radiation treatment. The growing demand for IORT offers patients expanded access to potentially lifesaving radiation therapy for their cancer treatment and an alternative to long-term radiation therapy.”
iCAD is an industry leader in helping healthcare professionals identify the most prevalent cancers earlier. The company offers a range of Computer-Aided Detection systems and workflow solutions for mammography, MRI, and CT applications. iCAD recently acquired Xoft, Inc., developer of the Axxent eBx system that uses non-radioactive miniaturized X-ray tube technology for the treatment of early stage breast cancer, skin cancer, and endometrial cancer. In addition, the system is cleared for use with other cancers or conditions where radiation therapy such as IORT is indicated.
For additional information, visit the company’s website at www.icadmed.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
